Allergan licenses neuropathic pain product to BMS
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb is to pay $40 million up front for global development, manufacturing and commercialisation rights to Allergan's neuropathic pain product AGN-209323.